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Abstract
Background: The use of antiemetics for children with vomiting is one of the most controversial decisions in the treatment of
gastroenteritis in developed countries. Ondansetron, a selective serotonin receptor antagonist, has been found to be
effective in improving the success of oral rehydration therapy. However, North American and European clinical practice
guidelines continue to recommend against its use, stating that evidence of cost savings would be required to support
ondansetron administration. Thus, an economic analysis of the emergency department administration of ondansetron was
conducted. The primary objective was to conduct a cost analysis of the routine administration of ondansetron in both the
United States and Canada.
Methods and Findings: A cost analysis evaluated oral ondansetron administration to children presenting to emergency
departments with vomiting and dehydration secondary to gastroenteritis from a societal and health care payer’s
perspective in both the US and Canada. A decision tree was developed that incorporated the frequency of vomiting,
intravenous insertion, hospitalization, and emergency department revisits. Estimates of the monetary costs associated with
ondansetron use, intravenous rehydration, and hospitalization were derived from administrative databases or emergency
department use. The economic burden in children administered ondansetron plus oral rehydration therapy was compared
to those not administered ondansetron employing deterministic and probabilistic simulations. We estimated the costs or
savings to society and health care payers associated with the routine administration of ondansetron. Sensitivity analyses
considered variations in costs, treatment effects, and exchange rates. In the US the administration of ondansetron to eligible
children would prevent approximately 29,246 intravenous insertions and 7,220 hospitalizations annually. At the current
average wholesale price, its routine administration to eligible children would annually save society US$65.6 million
(US$49.1–US$81.1) and health care payers US$61.1 million (US$46.2–US$76.3). In Canada the administration of ondansetron
to eligible children would prevent 4,065 intravenous insertions and 1,003 hospitalizations annually. Its routine
administration would annually save society CDN$1.72 million (CDN$1.15–CDN$1.89) and the health care system
CDN$1.18 million (CDN$0.88–CDN$1.41).
Conclusions: In countries where intravenous rehydration is often employed, the emergency department administration of
oral ondansetron to children with dehydration and vomiting secondary to gastroenteritis results in significant monetary
savings compared to a no-ondansetron policy.
Please see later in the article for the Editors’ Summary.
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The use of antiemetics for children with vomiting is one of the
most controversial decisions in the treatment of gastroenteritis in
developed countries [1]. Although oral rehydration therapy (ORT)
is recommended for children with mild to moderate dehydration,
it remains underused [1,2]. In one survey, over a third of
pediatricians indicated that vomiting is a contraindication to ORT
[3], while 86% of pediatric emergency medicine physicians who
responded to a survey indicated that they are more likely to
administer intravenous rehydration when vomiting is the major
symptom [4]. Physicians frequently prescribe antiemetic agents [5]
because they are interested in increasing the success of ORT and
reducing the discomforts of vomiting. However, antiemetic agents
commonly used in the 1990s such as promethazine and
prochlorperazine [5,6] are associated with frequent and potentially
life-threatening side effects [7], which resulted in a negative
perception of all antiemetics and a reduction in their use for
children with gastroenteritis.
Ondansetron, a selective serotonin receptor antagonist, has
been found to be effective in improving the success of ORT in
children with gastroenteritis [8–13]. A recent meta-analysis [14],
reported a decreased risk of further vomiting (absolute risk
reduction [ARR]=21%), intravenous rehydration (ARR=20%),
and immediate hospital admission (ARR=7%). An increase in
stool output without a concomitant increase in health care
utilization was reported in some studies. Despite these benefits,
clinical practice guidelines continue to recommend against the use
of antiemetics in gastroenteritis [1,2,15], stating that evidence of
cost savings would further support the argument for ondansetron
administration [1,2,14–17]. In April 2009, the National Institute
for Health and Clinical Excellence of the United Kingdom listed a
cost analysis as a key research priority in pediatric gastroenteritis
[15].
We conducted an economic analysis of the emergency
department (ED) administration of oral ondansetron to children
with vomiting and dehydration secondary to gastroenteritis. The
primary objective was to perform a cost analysis of the routine
administration of ondansetron in both the US and Canada; the
secondary objective was to assess, from a health care perspective,
the incremental cost of ondansetron per quality-adjusted life-year




A cost analysis was conducted to evaluate the overall costs of
routinely administering oral ondansetron to eligible children. In
this analysis, all costs are expressed in monetary terms. A cost-
utility analysis looking at the cost per QALY gained was
additionally conducted. In our model, the strategies compared
were administering ondansetron in addition to routine care (ORT)
versus ORT alone over a 1-y period for the entire populations of
Canada and the US.
A decision tree (Figure 1), was constructed to compare the two
treatment options—administering ondansetron and not adminis-
tering ondansetron in addition to ORT. Under the ‘‘yes’’ and ‘‘no’’
to ondansetron administration arms, vomiting could continue,
which could lead to intravenous rehydration and to hospitalization.
Children in both arms could be discharged to home and require a
repeat ED visit. The proportions experiencing the outcomes are
based on the efficacy of ondansetron (Table 1) [8–14]. Costs were
not discounted as the time horizon is less than 1 y [18].
The analyses were conducted from both the societal perspective
and the health care payer’s perspective. The former includes all
costs, both direct (the resources required to produce a service) and
indirect (productivity costs). Since similar medical resources,
management programs, and treatment guidelines are employed
in the US and Canada, but prices differ dramatically, separate
analyses were performed using data from each country.
Data Sources and Definition of the Study Population
The data sources included administrative data to derive the
number of ED visits and hospitalizations; administrative and
micro-costing data to derive costs; and meta-analysis and
randomized clinical trial data to determine the probability of
events.
For the US model, the number of annual gastroenteritis ED
visits was derived from the State Emergency Department
Databases (SEDDs) developed as part of the Healthcare Cost
and Utilization Project (HCUP) sponsored by the Agency for
Healthcare Research and Quality (AHRQ). The weighted
national estimate of the total number of admissions recorded in
the Kids’ Inpatient Database (KID) was used to calculate the
number of pediatric ED visits per year. Canadian estimates were
derived from the National Ambulatory Care Reporting System
(NACRS) available from the Institute of Clinical Evaluative
Sciences (ICES). Since estimates for ED visits were only available
for the province of Ontario, the national estimate was derived
from the number of ED visits multiplied by the proportion of the
Ontario to Canadian population less than 15 y old from the 2006
National Census [19]. In both countries, estimates of eligibility for
ondansetron treatment were derived using restrictive International
Classification of Diseases (ICD) codes (Text S1) and data from the
2005 calendar year [20].
A multinational expert panel concluded that 10%–15% of all
children presenting to EDs with acute gastroenteritis would meet
eligibility criteria for ondansetron administration as defined in the
clinical trials upon which efficacy estimates are based (mild to
moderate dehydration and recent vomiting). Given the uncertainty
around this estimate, a single centre, 4,000-patient chart review
(The Hospital for Sick Children) revealed that 16% of children
met eligibility criteria (unpublished data). Our analysis was
conducted assuming 10% of all children would be eligible to
reflect uncertainty across centres in this regard and ensure that our
estimate of benefit, if found, would be conservative.
Decision Model Parameters
The probabilities of events in the decision model and estimates
of ondansetron efficacy were based on the summary findings of a
recent meta-analysis [14] of ondansetron use in children with
gastroenteritis (Table 1). When the desired probabilities were
unavailable from the meta-analysis or previously published
randomized clinical trials [8–12], the authors of the studies were
contacted to provide the raw data (SBF, MJS, DMS) [8,9,14].
When estimates or assumptions were required, those that would
bias the results against ondansetron use were selected.
Costs
Medical costs included in the analysis were those related to
medication acquisition, dispensing, hospitalization, ED visits, and
intravenous rehydration (Table 2). Included in the cost estimates
were the costs of supplies, personnel, and nursing and physician
services. Nonmedical costs included were those related to foregone
earnings of parents, the consumption of special foods and oral
rehydration solution, extra diapers, and travel.
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gastroenteritis reported in KID is 2.1 d and the number of
workdays lost by the caregivers of children with gastroenteritis
evaluated in outpatient settings is 0.7–2 d [21–24]. We estimated
that an 8-h work day is lost for all outpatient visits not requiring
intravenous rehydration (no IV, home), that 16 h of work are lost
for all outpatient visits requiring intravenous rehydration but not
admission (IV, no admit, home), and that 24 h of work are lost per
child admitted (IV, admit, hospital).
For analysis purposes, the Canadian dollar was valued at
US$0.88 (2006) with a sensitivity range of (US$0.80–US$1.00). All
cost data reported are adjusted for use of 2006 as the base year.
Conversions were conducted using indices commonly employed to
adjust for inflation [25], the Bureau of Labor Statistics Consumer
Price Index Medical Care inflation rates [26,27], and the Statistics
Canada Health and Personal Care Consumer Price Index [28].
US: The point estimate charge for oral ondansetron adminis-
tration (US$26.57) was the average wholesale price (AWP) [29].
The AWP was selected as it is almost always greater than the
wholesale acquisition cost and lists prices that are much higher
than public or private payers are likely to pay, reflecting the
opportunity cost [30], and has been used previously for similar
analyses [31]. ED visit and hospitalization costs were derived from
the KID and the SEDD, respectively, from 2006. These data
sources reflect the amount the hospital charged for the entire
hospital stay (or ED services if using the SEDD), but do not
include professional fees. Hospital charges were then converted to
costs using the HCUP cost-to-charge ratios on the basis of hospital
accounting reports from the Centers for Medicare and Medicaid
Services. Intravenous insertion costs and physician fees were
derived from the 2008 Physicians’ Fee Reference 50th percentile
[32]. A proportional adjustment to the mean cost of an ED visit, as


































into two sections labeled (A) and (B). Entry into tree (A) requires that the child meet eligibility criteria (vomited on the day of presentation and evidence
of dehydration). The two strategies evaluated are presented after the decision node, indicated by a square in (A). Each possible outcome (i.e., vomiting,
intravenous rehydration) is presented on a tree branch after a chance node, shown as a circle on the tree. The complete tree is symmetrical beginning
from the left of (A) and moving to the right, through (B) with the ‘‘yes’’ and ‘‘no’’ arms being identical as represented by the number 1. The costs and
outcomes were entered at the payoff node, indicated by a triangle at the end of the models in both (A) and (B). An individual simulated patient can be
followed through the tree by starting with the treatment choice in (A) and moving through the tree. The patient will have the potential to develop an
outcome on the basis of the probabilities present at each chance node and are presented in Table 1. At the end of the tree, the total cost for that
simulated patient is calculated on the basis of the treatment received and the outcomes experienced. Yes implies ondansetron is administered to all in
addition to ORT; no implies standard of care (ORT) is administered but ondansetron is not administered. IV, intravenous.
doi:10.1371/journal.pmed.1000350.g001
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(25%) frequency of intravenous rehydration [33]. Nonmedical
costs included lost time from work valued at the parent’s wage
rate, calculated by multiplying the hourly wage by the number of
hours of work missed. Caregiver hourly wages were derived from
the June 2006 National Compensation Survey [34]. Length of
hospitalization was estimated from the 2006 KID and the number
of workdays lost by the caregivers of children with gastroenteritis
evaluated in outpatient settings was derived from the literature
[21–24]. Data regarding length of the ED stay was derived from
unpublished data collected during an earlier clinical trial [8].
Owing to the transient increase in diarrhea reported amongst
children treated with ondansetron [14], diaper costs were
estimated to be 33% greater in the ondansetron arm.
Canada: The point estimate cost for oral ondansetron
(CDN$13.09) was derived from the average of five Canadian
provincial drug benefit plans that reimburse for its use. Cost
estimates for ED visits, hospitalizations, and intravenous insertions
were derived from The Hospital for Sick Children’s ED and
inpatient average costs for supplies and personnel, and included
Ontario Health Insurance Plan physician billing costs for
consultation, continued care, ED visits, and nursing time when
appropriate. Wages for estimation of productivity costs were
derived from the Statistics Canada CANSIM database [35]. All
other cost estimates employed the same assumptions as described
above for the US.
Cost Analysis
Both deterministic estimates and probabilistic analyses were
undertaken to derive estimates of the value of an all-usage versus a
no-usage policy regarding ondansetron administration to eligible
children. The Monte Carlo microsimulation model used the
decision trees (Figure 1) with the associated probabilities and
distributions (Table 1), and costs (Table 2) associated with each
outcome. The number of trials used in the Monte Carlo
microsimulation model equaled the number of eligible children.
The Monte Carlo microsimulation model was created using Tree
Age Pro Suite 2009 (Data TreeAge Software Inc., Release 1.0.2,
2009).
One-way sensitivity analyses were conducted to determine how
the model’s results changed as the key assumptions were varied
over plausible ranges (75%–125%). Each one-way sensitivity
analysis was presented in a Tornado diagram to evaluate the
impact of the maximum and minimum expected values of all
probabilities and costs. Variables are ordered with those with the
broadest range of impact on the top; progressively narrower
ranges of impact are placed below, giving an appearance similar to
that of a tornado. The maximum variation in the variable deemed
to be most important in the tornado analysis was then employed
for sensitivity analysis purposes.
Table 2. Management costs for intervention and outcome
events used in the cost analysis and ranges considered.






ED visit 704 (528–879)
b 189 (141–236)
Physician costs, inpatient 273 (205–341) 183 (137–228)
Physician cost, ED 61.31 (45.98–76.64) 40.93 (30.70–51.16)
Intravenous insertion 194 (145–243) 84 (63–106)




19.29 (14.47–24.11) 18.55 (13.91–23.19)
Special food, ORS 24.00 (18.00–30.00) [37] 27.27 (20.45–34.09)
Extra diapers 9.00 (6.75–11.25) [37] 10.23 (7.67–12.78)
Travel 19.00 (14.25–23.75) [37] 21.59 (16.19–26.98)
Costs are adjusted to 2006 US$ and CDN$ respectively.
aData obtained from weighted national estimates from HCUP State inpatient
Databases (SID) 2005 and the AHRQ, on the basis of data collected by
individual states and provided to AHRQ by the states.
bData obtained from weighted estimate derived from SEDD 2005 and the AHRQ
on the basis of data collected by individual states and provided to AHRQ by
the states.
ORS, oral rehydration solution.
doi:10.1371/journal.pmed.1000350.t002
Table 1. Ondansetron efficacy estimates used in the cost analysis.










Vomiting Normal 15 36 10–19 30–42 [14]
Intravenous rehydration if vomits in ED Normal 41 47 25–58 35–58 [8,9]
Intravenous rehydration if no vomit in ED Normal 4 15 1–8 8–22 Data provided
by authors [8,9]
Admission to hospital if IV fluids administered
b Normal 23 30 8–37 20–41 Data provided
byauthors[8–10]
ED revisit Normal 12 10 8–17 6–15 Data provided
by authors [14]
Admission to hospital during revisit Gamma 44 29 26–65 13–51 Data provided
by authors [14]
Vomit initial dose of ondansetron (require
readministration)
Normal 5 0 1–9 0 Data provided
by authors [8]
a95% confidence intervals employed from meta-analysis data when available.
bAssumes that all children admitted from the ED received intravenous rehydration in the ED.
doi:10.1371/journal.pmed.1000350.t001
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The cost-utility analysis employed previously published QALY
estimates, which were derived on a cohort of 450 caregivers from
the US [36]. The available QALYs are for moderate (0.93) and
severe gastroenteritis (0.90), and these states closely resemble the
‘‘no IV, home’’ arm (moderate gastroenteritis) and the ‘‘IV, admit,
hospital’’ arm (severe gastroenteritis) (Figure 1). To avoid a bias in
favour of ondansetron the ‘‘IV, no admit, home’’ arm was assigned
values consistent with moderate gastroenteritis.
Results
Study Population
The proportion of gastroenteritis ED visits that result in
hospitalization in the US is 4.2%. Applying that proportion to
the weighted national estimate of the total number of admissions
yields a total number of 1,725,493 pediatric ED visits annually.
The number of Ontario ED visits was 95,017, and the proportion
of the Ontario to Canadian population less than 15 y old is 39.6%.
Thus, the annual number of Canadian ED visits is estimated to be
239,813. Employing our eligibility estimate (10%), the numbers of
children who are suitable for ondansetron administration are
172,549 in the US and 23,981 in Canada.
Cost Analysis
US: The administration of ondansetron to 10% of all children
with ED visits for acute gastroenteritis would prevent 29,246
(sensitivity analysis range, 22,122–32,556) intravenous insertions
and 7,220 (3,671–10,990) hospitalizations annually. The deter-
ministic model shows that total costs incurred from the health care
perspective in an all-ondansetron use pattern would be US$1,249
per patient (US$935–US$1,561), while a no-ondansetron use
pattern, would cost US$1,602 (US$1,202–US$2,002) per patient,
providing a net savings of US$353 (US$267–US$441) per patient
(Table 3). From a societal perspective, the total costs incurred from
an all-ondansetron use pattern would be US$1,500 per patient
(US$1,119–US$1,867), while a no-ondansetron use pattern would
cost US$1,879 (US$1,403–US$2,336), providing a net savings of
US$379 (US$284–US$469) per patient.
The probabilistic model revealed that for each child treated, the
total costs from an all-ondansetron use pattern was US$1,251
(US$935–US$1,564) while a no-ondansetron use pattern was
US$1,606 (US$1,205–US$2,003), saving the health care system
US$355 (US$270–US$439). From a societal perspective, the
health care system would cost US$1,500 (US$1,119–US$1,867)
from an all-ondansetron use pattern, while a no-ondansetron use
pattern would cost US$1,880 (US$1,402–US$2,334), leading to a
total saving of US$380 (US$283–US$467) for an all-ondansetron
use pattern.
The break-even total cost per dose of ondansetron administered
(where net savings are as likely as net costs) is US$362 (US$275–
US$450) from the health care payer and US$387 (US$293–
US$479) from the societal perspectives. At the current mean
average wholesale price [32] of US$26.57 per dose, its
administration to eligible children would result in a net savings
from the health care perspective of US$60.9 (US$46.1–US$76.1)
million under the deterministic and US$61.4 (US$46.6–US$75.7)
million under the probabilistic models for the entire US
population (Table 3). From a societal perspective, the savings
would be US$65.4 (US$49.0–US$80.9) and US$65.6 (US$48.8–
US$80.6) million under the deterministic and probabilistic models
respectively.
Canada: Ondansetron administration to all eligible children
would prevent 4,065 (3,075–4,525) intravenous insertions and
1,003 (510–1,528) hospitalizations annually. The deterministic
model shows that total costs incurred from the health care
perspective in an all-ondansetron use pattern would be CDN$331
(CDN$247–CDN$416) per patient, while a no-ondansetron use
pattern, would cost CDN$380 (CDN$284–CDN$475) per patient,
resulting in a net savings of CDN$49 (CDN$37–CDN$59) per
patient (Table 3). From a societal perspective, an all-ondansetron
use pattern would cost CDN$582 (CDN$395–CDN$662), while a
no-ondansetron use pattern would cost CDN$654 (CDN$443–
CDN$741) resulting in a net savings of CDN$72 (CDN$48–
CDN$79) per patient.
The probabilistic model revealed that an all-ondansetron use
pattern would cost CDN$330 (CDN$248–CDN$415), while a no-
ondansetron use pattern would cost CDN$378 (CDN$284–
CDN$475), saving the health care system CDN$48 (CDN$36–
Table 3. Cost analysis of ondansetron administration to children with vomiting and dehydration secondary to acute
gastroenteritis who are treated in an ED.
Economic Analysis Model and Perspective US: US$
a Canada: CDN$
a
Health Care Perspective-Deterministic Model
Net savings per patient 353 (267–441) 49 (37–59)
Net savings total population 60.9 million (46.1–76.1) 1.18 million (0.89–1.41)
Health Care Perspective-Monte Carlo Model
Net savings per patient 355 (270–439) 48 (36–60)
Net savings total population 61.4 million (46.6–75.7) 1.15 million (0.86–1.44)
Societal Perspective-Deterministic Model
Net savings per patient 379 (284–469) 72 (48–79)
Net savings total population 65.4 million (49.0–80.9) 1.72 million (1.15–1.89)
Societal Perspective-Monte Carlo Model
Net savings per patient 380 (283–467) 71 (47–76)
Net savings total population 65.6 million (48.8–80.6) 1.70 million (1.13–1.82)
aSensitivity analyses in parentheses. Costs are adjusted to 2006 US$ and CDN$ respectively.
doi:10.1371/journal.pmed.1000350.t003
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shows an all-ondansetron use pattern would cost CDN$583
(CDN$396–CDN$663), and a no-ondansetron use pattern would
cost CDN$654 (CDN$443–CDN$739), resulting in a savings of
CDN$71 (CDN$47–CDN$76).
From the health care perspective, ondansetron administration
would result in savings if it costs CDN$59 (CDN$49–CDN$72) or
less per dose. From the societal perspective, the break-even total
cost per dose administered is CDN$82 (CDN$60–CDN$91). At
the current mean provincial drug benefit plan reimbursement rate
of CDN$13.09, its administration to eligible children would result
in a net savings from the health care perspective of CDN$1.18
(CDN$0.89–CDN$1.41) million under the deterministic and
CDN$1.15 (CDN$0.86–CDN$1.44) million under the probabilis-
tic models for the entire Canadian population (Table 3). From a
societal perspective, the savings using a deterministic model would
be CDN$1.72 (CDN$1.15–CDN$1.89) million and CDN$1.70
(CDN$1.13–CDN$1.82) million under the probabilistic models,
respectively.
Sensitivity Analysis
When varying individual variables (Table 4), the savings range
from US$151–US$576 in the US and CDN$20–CDN$82 in
Canada. In both countries, the tornado diagrams (Figure 2) reveal
that the cost of the ED visit had the greatest impact on both the
ondansetron and no-ondansetron pathways. Varying the cost of
physician inpatient fees had the smallest impact in the models.
Cost-Utility Analysis
For every additional ondansetron tablet used, 0.0015 (0.00085–
0.0022) QALYs would be gained. In the US, an all-ondansetron
administration policy would result in 160,677 (160,308–160,850)
QALYs per year, while a no-ondansetron usage policy would
result in 160,411 (159,930–160,703) QALYs per year, resulting in
a net gain of 266 (146–377) QALYs per year. In Canada, an all-
ondansetron usage pattern would result in 22,198 (22,147–22,221)
QALYs per year, while a no-ondansetron usage pattern would
result in 22,161 (22,094–22,201) QALYs per year, resulting in a
net gain of 37 (20–52) QALYs per year. Since the program results
in a net cost reduction, we did not evaluate the cost per QALY
gained.
Discussion
We estimate that every year, oral ondansetron administration to
eligible children in the ED would prevent intravenous insertion in
approximately 30,000 children in the US and 4,000 in Canada.
Over 8,000 admissions per year would be avoided in these
countries combined. Ondansetron administration to the appro-
priate group of children would additionally result in an
Table 4. Range of costs associated with maximal variation in individual parameters included in model.
Focus of Sensitivity Analysis










Physician cost, inpatient 350–356 46–51
Physician cost, ED 353–354 48–49
ED visit 349–358 48–50




IV insertion if vomits 271–432 36–63
IV insertion if does not vomit 288–402 39–59
Admission if IV fluids administered 252–461 35–65
ED revisits 243–441 27–69
ED revisit resulting in admission 274–421 38–59
Vomiting initial dose of ondansetron 352–354 49–50
Proportions: Ondansetron not administered
Vomiting 306–401 41–57
IV insertion if vomits 246–452 31–66
IV insertion if does not vomit 242–465 30–68
Admission if IV fluids administered 151–576 20–82
ED revisits 288–435 34–68
ED revisit resulting in admission 306–418 42–59
aDue to nearly identical data for health care and societal perspectives, we have displayed only health care perspective to facilitate clarity. Costs are adjusted to 2006
US$ and CDN$ respectively.
IV, intravenous.
doi:10.1371/journal.pmed.1000350.t004
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per year in the US and CDN$1.7 million in Canada. Thus, it is
clear that ondansetron administration to children with vomiting
and dehydration in the ED is a dominant strategy (i.e. ondansetron
administration results in improved outcomes and reduced costs).
Several systematic reviews have evaluated the evidence of
benefit derived from the use of ondansetron, and while they all had
similar findings, their endorsement of ondansetron use was made
in conjunction with the need for an economic analysis. The 2009
Cochrane Review included four clinical trials, did not include a
meta-analysis, and had a primary objective that was not dealt with
by any of the studies (time to achieve cessation of vomiting) [17].
The review concluded that while ondansetron may reduce the
amount of vomiting, and the numbers of children requiring
intravenous rehydration and hospitalization, it stressed the need to
conduct a cost analysis [17]. A meta-analysis published in 2007,
which also included four trials, concluded that ondansetron use is
associated with some clinical benefit [16]. However, the authors
state that there is insufficient evidence to recommend the routine
use of ondansetron and that future studies need to address the
economic implications of using ondansetron. A more recent
systematic review and meta-analysis, which included six studies,
concluded that the symptomatic relief and avoidance of invasive
therapies seen with ondansetron use suggest that it is beneficial
when administered to moderately ill children with gastroenteritis.
This meta-analysis included a study that was excluded from the
Cochrane Review because of the inclusion of participants up to the
age of 22 y [12], and a study that appears to have not been
retrieved by their search strategy [11]. It additionally included two
studies [10,11] not included in the earlier meta-analysis [16].
Thus, the meta-analysis [14] data upon which our effectiveness
estimates are based are the most complete in the literature and
more definitively recommend the ED use of ondansetron.
Nonetheless, even the authors of the meta-analysis with the
strongest conclusions state that formal cost analyses should be
performed [14]. Thus, our data answer the important questions
raised in these recent reviews and can be employed to aid
clinicians and health care administrators when making decisions at
patient and societal levels.
We can compare the economic implications of our findings to
the benefits incurred from other therapies employed in the
treatment of pediatric gastroenteritis. For example, the now
endorsed US rotavirus vaccination program requires the admin-
istration of three vaccine doses to 4 million infants to result in
Figure 2. Tornado diagram showing the influence of changing values of any variable on per patient costs. Tornado diagram showing
the influence of changing values of any variable on per patient costs when other variables remain at their base values. In the graph, variables are
ranked on the basis of their influence (the most influential variable is on the top). Only variables that had more than 1% effect in the expected value
were included. IV, intravenous.
doi:10.1371/journal.pmed.1000350.g002
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of ondansetron to 172,549 children in the US (4% as many as the
vaccine program) would result in approximately 8,000 fewer
admissions (18% as many as the vaccine program). In addition, the
rotavirus vaccination program would cost an extra US$515 million
to the health care system, while routine ondansetron administra-
tion would save the health care system US$61 million. On a
patient outcome level, the benefits of ondansetron administration
can be compared with those seen with the use of zinc, which is
endorsed by the World Health Organization and United Nations
Children’s Fund [39]. Using the Lives Saved Tool methodology,
zinc administration to children with diarrhea in developing
countries is estimated to decrease the relative risk of hospitaliza-
tions by 23% (95% confidence interval [CI] 15%–31%) [40],
while the benefit seen with ondansetron administration in
developed countries is a 48% relative risk reduction (95% CI
18%–67%). As ondansetron use is a dominant strategy, being both
clinically and economically beneficial, its use, in the appropriate
clinical situation should be encouraged.
The National Institute for Health and Clinical Excellence
conducted a probabilistic sensitivity analysis and found that the
results were not sensitive to parameter uncertainty with ondan-
setron being the dominant strategy in 99.96% of the simulations
[15]. However, their model did not incorporate the cost of
increased diarrheal events, repeat medication administration due
to vomiting, and the need for future hospital visits and the
outcomes at those encounters. Despite incorporating these
elements into our model, and conducting our analysis employing
cost estimates from two different countries, our findings were
similar. We did, however, detect a significant difference in break-
even prices between countries. This difference is primarily driven
by the large role played by the cost of hospitalization in the US,
which is approximately 8-fold that in Canada, and the 4-fold
difference in ED visits.
Our study has several limitations in the estimates of disease
burden and costs. While the numbers of potentially eligible
patients were derived from large databases, our primary analysis
assumed that only 10% of children with gastroenteritis who
present to an ED would meet eligibility criteria. This number is
likely an underestimation based on analysis of all cases of
gastroenteritis at a Canadian institution where 16% were found
to be eligible and a report from two EDs in the US where
ondansetron was administered to 58% of more than 34,000
children with gastroenteritis [41]. We additionally did not include
estimates on the use of ondansetron in the clinic or private office
setting as estimates of eligibility and efficacy are not available,
though such use is becoming very common [42]. Thus, our
conclusions likely underestimate the total societal savings from the
appropriate use of ondansetron.
This analysis focused on a specific population of children with
vomiting and clinical evidence of dehydration evaluated in an ED
setting. The results should not be extrapolated to children without
evidence of dehydration as these children are less likely to
experience the costly outcomes of intravenous rehydration and
hospitalization. Additionally, no clinical data exist to support the
administration of multiple doses of ondansetron or its use in the
clinic or private office settings. While accepted as a very safe class
of drugs, serotonin receptor antagonists may cause minor side
effects such as constipation, diarrhea, headaches, and light-
headedness [43]; rarely, they may be associated with more severe
reactions [44,45].
While it is clear that vomiting is a frequent cause of ORT failure
in developed countries leading to the use of intravenous
rehydration and hospitalization, clinicians working in developing
nations do not find vomiting to be as significant a barrier to the
success of ORT. In fact, the overall acceptance of ORT in
countries such as the US, has lagged far behind that in many
developing countries [46]. Although meta-analyses of clinical trials
conducted in developed countries have documented only a 5%
ORT failure rate, this is much lower than what happens outside of
oral rehydration clinical trials [47]. This finding is evidenced by
the 34% failure rate in the placebo groups in the ondansetron
clinical trials [14], despite claiming that appropriate ORT
protocols were followed. A multitude of explanations are possible
for this discrepancy; however, a key variable is the preference of
parents in the US for the administration of intravenous
rehydration [48]. However, of those parents who selected
intravenous rehydration, 53% stated that they would choose oral
rehydration if an oral medication were available that would
significantly decrease vomiting. Thus, it seems that ondansetron
may play a key role in promoting the use of ORT in environments
where the overall usage of ORT is suboptimal. Hence, at present,
usage of ondansetron in children with gastroenteritis should be
limited in the developing world where the emphasis should remain
on ORT alone.
The strengths of this study include the use of original data,
which allowed us to estimate the frequency of outcomes not
previously reported. Despite using wide margins of error in the
sensitivity analysis, the conclusions did not change significantly.
Lastly, our conclusions are strengthened because the analysis
included cost estimates from two countries, with different health
care systems. Despite this important economic distinction, our
analysis concluded that ondansetron administration would result
in cost savings in both countries.
In addition to being clinically beneficial, the administration of
oral ondansetron to children with dehydration and vomiting
secondary to infectious gastroenteritis is economically advanta-
geous, making it a dominant treatment strategy. On the basis of
the available clinical data and our cost analysis, the use of
ondansetron should become routine in North American EDs in
order to reduce both the burden of disease on children and the
costs to society and health care systems.
Supporting Information
Text S1 International Classification of Diseases (ICD) coding
employed to derive estimates of eligibility for ondansetron
treatment. ICD-9 CM coding was employed in the US, while
ICD-10 coding was employed to derive Canadian estimates.
Found at: doi:10.1371/journal.pmed.1000350.s001 (0.02 MB
DOC)
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Background. Although many episodes of gastroenteritis in
children are mild and can be managed with oral fluids,
including oral rehydration therapy (ORT), some cases are
severe enough to require hospital admission for intravenous
fluids. Administration of an antiemetic (a drug that reduces
nausea and sickness) can be clinically effective, especially
ondansetron, (a drug that belongs to a class of drugs known
as selective serotonin receptor antagonists), which is safer
than other antiemetics, such as promethazine and
prochlorperazine, and in which there is good evidence to
support its effectiveness in improving the success of ORT in
children with gastroenteritis. Furthermore, studies have
shown that administration of ondansetron decreases the
risk of further vomiting, and hence the need for intravenous
rehydration, and immediate hospital admission. However,
despite the proven clinical benefits of ondansetron, clinical
practice guidelines continue to recommend against the use
of antiemetics in gastroenteritis because the evidence of cost
savings is not yet clear. Last year, the UK’s National Institute
for Health and Clinical Excellence recommended that such a
cost analysis should be a key research priority in pediatric
gastroenteritis.
Why Was This Study Done? This study—which is an
economic analysis—was conductedin response to the various
calls for the need to demonstrate the cost effectiveness of
ondansetron in the management of pediatric gastroenteritis.
What Did the Researchers Do and Find? The researchers
analysed the costs of the administration of oral ondansetron
in both the US and Canada, if routinely given to children with
gastroenteritis-induced vomiting and dehydration in the
emergency department setting. In addition, the researchers
calculated the incremental cost of ondansetron per quality-
adjusted life-year (QALY) gained from a health care
perspective, compared to a regimen without ondansetron
administration. The authors conducted a particular type of
statistical analysis, known as decision tree analysis, to
compare the two treatment options—administering ondan-
setron and not administering ondansetron in addition
to ORT, with the clinical outcomes (further vomiting,
intravenous rehydration, and hospitalization) determined
on the basis of the documented efficacy of ondansetron. In
addition, the researchers conducted their analyses from both
the societal perspective (which included all costs, both
direct—the resources required to produce a service; and
indirect—productivity costs) and the health care payer’s
perspective. The US and Canada use similar medical
resources, management programs, and treatment guide-
lines, but as prices differ dramatically (for example, the cost
of hospitalization in the US is 8-fold higher than that in
Canada), the researchers conducted a separate analysis for
each country.
On the basis of data from the US, the researchers found that
the administration of ondansetron to eligible children would
prevent approximately 29,246 intravenous insertions and
7,220 hospitalizations every year with an annual saving of
US$65.6 million to society and US$61.1 million to payers of
health care costs if this drug was given routinely. When using
Canadian data, the researchers found that the administration
of ondansetron to eligible children would prevent 4,065
intravenous insertions and 1,003 hospitalizations every year,
with an annual saving of CDN$1.72 million to society and
CDN$1.18 million to payers of health care costs if this drug
was given routinely.
What Do These Findings Mean? The results of this study
show that the emergency department administration of oral
ondansetron to children with dehydration and vomiting
secondary to gastroenteritis results in significant monetary
savings from both societal and health care perspectives
compared to a policy that does not include ondansetron
administration. Furthermore, the societal savings are
probably an underestimate because in their model, the
researchers assumed that only 10% of children with
gastroenteritis presenting to an emergency department
would meet eligibility criteria (in reality, this proportion
would likely be higher). In addition, the researchers did not
include estimates for ondansetron administration in the
clinic or private office setting, as although such use is
common, no estimates of eligibility and efficacy were
available.
Therefore, in addition to being clinically beneficial, the
administration of oral ondansetron to children with dehy-
dration and vomiting secondary to gastroenteritis is also
economically advantageous.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000350.
N Patient UK and the US National Institutes of Health provide
information for patients on ondansetron
N Patient UK provides information on gastroenteritis in
children
N BBC Health also provides general information on
gastroenteritis
N The Centers for Disease Control and Prevention contains a
report on managing acute gastroenteritis among children
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